Vigorous LDL cholesterol targets now set for secondary prevention of CVD

+Practice
In print
HEARTBEAT

Vigorous LDL cholesterol targets now set for secondary prevention of CVD

Chris Ellis

Chris Ellis

Heartbeat ECG
ECG: Supplied

Consultant cardiologist Chris Ellis discusses the recent funding of rosuvastatin, focusing on its use for secondary prevention of cardiovascular disease

Key points, Rosuvastatin 40mg will lower the LDL cholesterol level by approximately 63 per cent, compared with about 55 per cent with atorvastatin 80mg. Ezetimi, Pract Green w Pale Yellow
References

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):11188.